Abstract

Background: Genetic variations in the carnosinase-1 gene, which may also be associated with cardiovascular issues and result in a higher serum carnosinease-1 level, may affect the levels of carnosine and carnosine synthase in diabetes patients. Objective: To examine the impact of the Carnosineas-1 gene polymorphism SNP (rs 2887) on blood levels of carnosine and carnosine synthase-1 and their relationship to CVD in diabetes. Method: The serum concentrations of carnosine and carnosineas-1 were determined using ELISA-specific kits. The carnosineas-1 gene (CN1) was subjected to the high-resolution melt technique (HRM) with the purpose of identifying gene polymorphisms. Results: Carnosinase-1 levels were considerably raised in the T2DM with CVD group, but serum carnosine levels were significantly higher in both groups. SNPs had little impact on serum carnosine levels, whereas polymorphisms had a big impact on carnosinase-1 levels. Conclusion: By raising serum levels of carnosenease-1, which in turn increases carnosine breakdown, the SNP (rs2887) of the carnosinase-1 gene contributes indirectly to the development of CVD in T2DM.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call